Lurbinectedin 4 MG Injection [Zepzelca]

DRUG2 trials

Sponsors

HonorHealth Research Institute, National Cancer Center, Korea

Conditions

Gastrointestinal MalignanciesNeuroendocrine Tumor of PancreasPancreatic Neuroendocrine Tumors

Phase 2

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

CompletedNCT05229588

HonorHealth Research InstituteGastrointestinal Malignancies

Start: 2022-06-14End: 2025-08-04Updated: 2026-09-11

Patients With High-grade Pancreatic Neuroendocrine Tumors

Enrolling by invitationNCT07121478

National Cancer Center, KoreaNeuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors

Start: 2025-09-23End: 2029-12-31Target: 46Updated: 2025-10-01